Lorus Therapeutics Inc
LRUSF:OTCQB
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 0.323 | 0.00 0.00% | 0.00% | 0 | 178 |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Lorus Therapeutics Inc
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year
2013
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Corporation"),
a biopharmaceutical company specializing in the research and
development of pharmaceutical products and technologies for the
management of cancer, today reported financial results for the three
and six months ended November 30, 2012.
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2013
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and six months ended November 30, 2012.
Lorus Therapeutics announces dose escalation of Phase I cancer study
View more recent headlinesLorus Therapeutics Inc., a biopharmaceutical company, has announced that its Phase I clinical study of LOR-253 has escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
Company Background
Lorus Therapeutics Inc. (Lorus) is a biopharmaceutical company. The Company is a discovery, research and clinical development-stage company with a focus on cancer drugs. The Company has an active portfolio, including small molecules (LOR-253/LOR-500) and an immunotherapy (IL-17E). Lorus has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to a product available to start a Phase III clinical trial. Lorus has one subsidiary, NuChem Pharmaceuticals Inc. (NuChem).
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 0.00 | Previous Close 0.323 |
Day High 0.00 | Day Low 0.00 |
52wk High/Date 0.595 / 5/1/2012 | 52wk Low/Date 0.1701 / 2/2/2012 |
% off 52wk High -45.71% | % off 52wk Low 89.89% |
Beta (5 Yr) 1.5 | Market Capitalization 13.6M |
Shares Outstanding 42.3M | Volatility Avg 0.00 |
EPS(TTM) -0.17 | P/E Ratio Not Meaningful |
Dividend Announcement -- | Yield 0.00% |
Ex-Date -- | Date of Record -- |
Payable 0.00 - -- | Payable Date -- |
Last Trade as of 1/17/2013 1:13 PM ET | |
LRUSF Lorus Therapeutics Inc vs. Peers
| Peers | |
|---|---|
LRUSF Lorus Therapeutics Inc | 6.25% |
Celgene Corporation | 25.13% |
Biogen Idec Inc. | -1.81% |
ISIS Pharmaceuticals, Inc. | 35.73% |
Idera Pharmaceuticals Inc | -15.60% |
LRUSF Lorus Therapeutics Inc | 0.00% |
Celgene Corporation | -- |
Biogen Idec Inc. | -- |
ISIS Pharmaceuticals, Inc. | -- |
Idera Pharmaceuticals Inc | -- |
LRUSF Lorus Therapeutics Inc | 0.00% |
Celgene Corporation | 1.87% |
Biogen Idec Inc. | 0.39% |
ISIS Pharmaceuticals, Inc. | 1.34% |
Idera Pharmaceuticals Inc | -1.49% |